Excitatory amino acid antagonists and memory: Effect of drugs acting at receptors in learning and memory tasks
References (22)
Dissociation of disinhibitory effects of scopolamine: strain and task factors
Pharmac. Biochem. Behav.
(1975)- et al.
Amnesic effect of the novel anticonvulsant MK-801
Pharmac. Biochem. Behav.
(1988) - et al.
Muscle relaxant action of excitatory amino acid antagonists
Neurosci. Lett.
(1985) - et al.
Long-term potentiation and NMDA receptors in rat visual cortex
Nature, Lond.
(1987) - et al.
2-Amino-7-phosphonoheptanoic acid (AP7) produces discriminative stimuli and anticonflict effects similar to diazepam
Life Sci.
(1986) - et al.
Anticonvulsant activity of (+)-5-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine (MK-801), a substance with potent anticonvulsant, central sympathomimetic and apparent anxiolytic properties
Drug Dev. Res.
(1982) - et al.
Anticonvulsant action of excitatory amino acid antagonists
Science, Wash.
(1982) - et al.
The role of NMDA receptors in certain kinds of learning
- et al.
Homogeneity of single trial response tendencies and spontaneous alternation in the T-maze
Psych. Rep.
(1965) - et al.
CGS 19755, a selective and competitive NMDA-type excitatory amino acid receptor antagonist
J. Pharmac. exp. Ther.
(1988)
CPP, a selective (NMDA)-type receptor antagonist: characterization in vitro and in vivo
J. Pharmac. exp. Ther.
Cited by (170)
Protective effects of SGB121, ginsenoside F1-enriched ginseng extract, on scopolamine-induced cytotoxicity and memory impairments
2020, Journal of Functional FoodsCitation Excerpt :Interestingly, the effect of 100 mg/kg SGB121 on spontaneous alternation behaviors was higher than that of 200 mg/kg SGB121 or tacrine. No significant difference was observed in the total number of arm entries across all experimental groups (Fig. 4C), demonstrating that the general locomotor activity was not affected (Parada-Turska & Turski, 1990; Pellow, Chopin, File, & Briley, 1985). Furthermore, there was no correlation observed between the total number of arm entries and Y-maze alternation, indicating that the difference in the total number of arm entries did not impact the quantification of spontaneous alternation in the Y-maze.
ASP5736, a novel 5-HT<inf>5A</inf> receptor antagonist, ameliorates positive symptoms and cognitive impairment in animal models of schizophrenia
2014, European NeuropsychopharmacologyCitation Excerpt :We also evaluated the effect of this compound in combination with olanzapine on spontaneous alternation behavior. Administration of MK-801 consistently induced a marked decrease in the alternation rate in the Y-maze test in each experiment (P<0.001, by Student׳s t-test), as coinciding with previous results (Parada-Turska and Turski, 1990). ASP5736 significantly attenuated the MK-801-induced decrease in alternation rate, and statistical analysis revealed that the effect of ASP5736 was significant at doses of 0.001 and 0.003 mg/kg (p.o.) (Figure 3A).
Predictive validity of a MK-801-induced cognitive impairment model in mice: Implications on the potential limitations and challenges of modeling cognitive impairment associated with schizophrenia preclinically
2014, Progress in Neuro-Psychopharmacology and Biological PsychiatryCitation Excerpt :In rodents, NMDA receptor antagonists produce behavioral disturbances suggested to mimic schizophrenia, including impaired sensorimotor gating (for review, see Geyer et al., 2001), reduced social interaction (for review, see Sams-Dodd, 1999), and importantly for CIAS research, neurocognitive deficits (for review, see Large, 2007). The memory-impairing effects of MK-801, a potent non-competitive NMDA receptor antagonist, in IA (MK-IA) are well documented (Benvenga and Spaulding, 1988; Brown et al., 2013; Jones et al., 1990; Parada-Turska and Turski, 1990; Venable and Kelly, 1990), yet the pharmacological predictive validity of the model for CIAS has not been thoroughly investigated nor established. We sought to systematically test the effects of atypical antipsychotics, sodium channel blocker mood stabilizers, and putative cognitive-enhancing drugs which have been tested clinically for effects on cognition in schizophrenia patients in MK-IA to enable an empirical assessment of the predictive validity of the model.
A polyamine-deficient diet opposes hyperalgesia, tolerance and the increased anxiety-like behaviour associated with heroin withdrawal in rats
2013, Pharmacology Biochemistry and BehaviorGroup II metabotropic glutamate receptor agonists and positive allosteric modulators as novel treatments for schizophrenia
2012, NeuropharmacologyCitation Excerpt :In rodents, sub-anesthetic doses of NMDA receptor antagonists selectively increase brain excitation in limbic brain regions (e.g., mPFC, hippocampus, and cingulate cortex) and afferent projection sites such as the thalamus and nucleus accumbens (Moghaddam et al., 1997; Moghaddam and Adams, 1998). Behavioral effects of NMDA antagonists manifest as increases in locomotor activity and stereotypies (Danysz et al., 1994; Moghaddam et al., 1997) and impaired cognition (Danysz et al., 1988; Parada-Turska and Turski, 1990). The ability of selective mGlu2/3 receptor agonists to reverse the locomotor stimulating effects of PCP was first demonstrated by Moghaddam and Adams (1998).